You just read:

Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig™ (erenumab-aooe) In Patients With Chronic And Episodic Migraine

News provided by

Amgen

Jun 28, 2018, 04:30 ET